Lupin closes VISUfarma deal, but can branded ophthalmology drive the next phase of growth?

Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.

Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.